FI950889A0 - Antianginaaliset pyridopyrimidinoniaineet - Google Patents

Antianginaaliset pyridopyrimidinoniaineet

Info

Publication number
FI950889A0
FI950889A0 FI950889A FI950889A FI950889A0 FI 950889 A0 FI950889 A0 FI 950889A0 FI 950889 A FI950889 A FI 950889A FI 950889 A FI950889 A FI 950889A FI 950889 A0 FI950889 A0 FI 950889A0
Authority
FI
Finland
Prior art keywords
alkyl
pct
co2r9
onyl
morpholino
Prior art date
Application number
FI950889A
Other languages
English (en)
Swedish (sv)
Other versions
FI112484B (fi
FI950889A (fi
Inventor
Andrew Simon Bell
Nicholas Kenneth Terrett
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI950889A0 publication Critical patent/FI950889A0/fi
Publication of FI950889A publication Critical patent/FI950889A/fi
Application granted granted Critical
Publication of FI112484B publication Critical patent/FI112484B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
FI950889A 1992-08-28 1995-02-27 Menetelmä 2-(2-alkoksifenyyli)pyrido[3,2-d]pyrimidin-4(3H)-onijohdannaisten valmistamiseksi FI112484B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929218322A GB9218322D0 (en) 1992-08-28 1992-08-28 Therapeutic agents
GB9218322 1992-08-28
EP9302097 1993-08-04
PCT/EP1993/002097 WO1994005661A1 (en) 1992-08-28 1993-08-04 Pyridopyrimidinone antianginal agents

Publications (3)

Publication Number Publication Date
FI950889A0 true FI950889A0 (fi) 1995-02-27
FI950889A FI950889A (fi) 1995-02-27
FI112484B FI112484B (fi) 2003-12-15

Family

ID=10721102

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950889A FI112484B (fi) 1992-08-28 1995-02-27 Menetelmä 2-(2-alkoksifenyyli)pyrido[3,2-d]pyrimidin-4(3H)-onijohdannaisten valmistamiseksi

Country Status (12)

Country Link
US (1) US5591742A (fi)
EP (1) EP0656898B1 (fi)
JP (1) JP2660103B2 (fi)
AT (1) ATE148118T1 (fi)
CA (1) CA2138298C (fi)
DE (1) DE69307712T2 (fi)
DK (1) DK0656898T3 (fi)
ES (1) ES2096936T3 (fi)
FI (1) FI112484B (fi)
GB (1) GB9218322D0 (fi)
GR (1) GR3022852T3 (fi)
WO (1) WO1994005661A1 (fi)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298518A (en) * 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
WO1997043287A1 (en) * 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
TR199902646T2 (xx) 1997-04-25 2000-05-22 Pfizer Inc. Seks�el bozuklu�un tedavisi i�in pirazolopirimidinonlar.
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
BR9812785A (pt) * 1997-11-12 2000-10-10 Bayer Ag "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase"
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
CN1229349C (zh) 1998-04-20 2005-11-30 美国辉瑞有限公司 吡啶－3－羧酸衍生物
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
JP2003511452A (ja) 1999-10-11 2003-03-25 ファイザー・インク ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BR0017043A (pt) * 1999-12-24 2003-01-07 Bayer Ag Imidazo[1,3,5]triazinonas e sua aplicação
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
WO2001087888A1 (en) * 2000-05-17 2001-11-22 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20040102324A1 (en) 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
HUP0303183A2 (hu) * 2001-03-05 2003-12-29 E.I. Du Pont De Nemours And Company Gerinctelen kártevőírtó hatású heterociklusos diamidszármazékok, azokat tartalmazó készítmények és alkalmazásuk
DK1392314T3 (da) * 2001-05-09 2007-03-12 Bayer Healthcare Ag Hidtil ukendt anvendelse af 2-[2-ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-on
ATE455758T1 (de) 2001-12-20 2010-02-15 Merck Serono Sa Pyrrolidin-derivatie als prostaglandin- modulatoren
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR100490970B1 (ko) * 2002-03-22 2005-05-24 씨제이 주식회사 신규 피리도[2,3-ｄ]피리미딘 카르보알데히드 옥심계ＰＤＥ Ⅳ 효소 저해 화합물 및 이의 제조방법
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
CA2529307C (en) * 2003-06-13 2013-12-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
JP2008533192A (ja) 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
PL1881985T3 (pl) 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
JP2010532319A (ja) * 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013115884A2 (en) 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
JPS5393520A (en) * 1977-01-24 1978-08-16 Shin Meiwa Ind Co Ltd Canopy device for rear body of vehicle
SE406624B (sv) * 1977-07-12 1979-02-19 Stal Laval Turbin Ab Turbomaskin
JPS5670998A (en) * 1979-11-15 1981-06-13 Toppan Printing Co Ltd Laser carving method and mask board used for said method
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
JPH0216563U (fi) * 1988-07-19 1990-02-02
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
DK0656898T3 (da) 1997-08-18
JP2660103B2 (ja) 1997-10-08
FI112484B (fi) 2003-12-15
GB9218322D0 (en) 1992-10-14
ATE148118T1 (de) 1997-02-15
GR3022852T3 (en) 1997-06-30
FI950889A (fi) 1995-02-27
CA2138298C (en) 1998-04-14
EP0656898A1 (en) 1995-06-14
US5591742A (en) 1997-01-07
WO1994005661A1 (en) 1994-03-17
DE69307712T2 (de) 1997-05-15
ES2096936T3 (es) 1997-03-16
DE69307712D1 (de) 1997-03-06
JPH07506838A (ja) 1995-07-27
EP0656898B1 (en) 1997-01-22
CA2138298A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
FI950889A0 (fi) Antianginaaliset pyridopyrimidinoniaineet
CA2122360A1 (en) Quinazolinone Antianginal Agents
CA2044748A1 (en) Pyrazolopyrimidinone antianginal agents
TW358096B (en) Pyrazolopyridimidinone antianginal agents
FI946083A (fi) Antianginaaliset purinonit
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
DK0678090T3 (da) Piperazinderivater
YU60993A (sh) Benzenalkanske kiseline za kardiovaskularna oboljenja
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister

Legal Events

Date Code Title Description
MA Patent expired